Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Macdougall, I. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Macdougall, I. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2000) 15: 1743-1745
© 2000 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

Intravenous administration of iron in epoetin-treated haemodialysis patients—which drugs, which regimen?

Iain C. Macdougall

Department of Renal Medicine, King's College Hospital, London, UK

Introduction

There has been a plethora of literature on iron management in erythropoietin (Epo)-treated patients in recent times [1–9]. This includes published original clinical research [1–3], state-of-the-art reviews [4–7], and clinical guidelines generated by advisory committees on both sides of the Atlantic [8,9]. If we were to summarize in one statement the main message from all this literature we would conclude: ‘still no reliable laboratory test for iron deficiency; oral iron of limited use; need for regular and frequent i.v. iron in the majority of patients on Epo’.

With all this published information, why then have the editors felt the need to commission yet another article? (The request was for ‘a short and snappy piece that can be read over a cup of coffee’! E. Ritz, personal communication.) Is the message recommending the regular use . . . [Full Text of this Article]

Are all i.v. iron preparations the same?

Which i.v. iron preparation to use?

Which treatment regimen to use?

Need for a test dose?

Conclusions

Acknowledgments

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
N. Ternes, B. Scheiber-Mojdehkar, G. Landgraf, H. Goldenberg, and B. Sturm
Iron availability and complex stability of iron hydroxyethyl starch and iron dextran a comparative in vitro study with liver cells and macrophages
Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2824 - 2830.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. Kletzmayr, G. Sunder-Plassmann, and W. H. Horl
High dose intravenous iron: a note of caution
Nephrol. Dial. Transplant., June 1, 2002; 17(6): 962 - 965.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. Shaldon and I. C. Macdougall
Intravenous administration of iron in epoetin-treated haemodialysis patients
Nephrol. Dial. Transplant., May 1, 2001; 16(5): 1076 - 1077.
[Full Text] [PDF]